Literature DB >> 27363336

High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism.

Amit Subedi1, Yushi Futamura2, Mayuko Nishi3, Akihide Ryo3, Nobumoto Watanabe4, Hiroyuki Osada5.   

Abstract

Cancer stem cells (CSCs) have robust systems to maintain cancer stemness and drug resistance. Thus, targeting such robust systems instead of focusing on individual signaling pathways should be the approach allowing the identification of selective CSC inhibitors. Here, we used the alkaline phosphatase (ALP) assay to identify inhibitors for cancer stemness in induced cancer stem-like (iCSCL) cells. We screened several compounds from natural product chemical library and evaluated hit compounds for their efficacy on cancer stemness in iCSCL tumorspheres. We identified artesunate, an antimalarial drug, as a selective inhibitor of cancer stemness. Artesunate induced mitochondrial dysfunction that selectively inhibited cancer stemness of iCSCL cells, indicating an essential role of mitochondrial metabolism in cancer stemness.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Artesunate; CSCs; High-throughput screening; Mitochondrial metabolism; Tumorspheres

Mesh:

Substances:

Year:  2016        PMID: 27363336     DOI: 10.1016/j.bbrc.2016.06.128

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism.

Authors:  Ling Ma; Honghua Fei
Journal:  J Bioenerg Biomembr       Date:  2020-02-08       Impact factor: 2.945

Review 2.  Correlation between amino acid metabolism and self-renewal of cancer stem cells: Perspectives in cancer therapy.

Authors:  Qi Zhang; Wei Li
Journal:  World J Stem Cells       Date:  2022-04-26       Impact factor: 5.247

3.  Artesunate targets oral tongue squamous cell carcinoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition.

Authors:  Qingfeng Xiao; Lei Yang; Hao Hu; Yue Ke
Journal:  J Bioenerg Biomembr       Date:  2020-01-21       Impact factor: 2.945

Review 4.  Emerging agents that target signaling pathways in cancer stem cells.

Authors:  Yue Yang; Xiaoman Li; Ting Wang; Qianqian Guo; Tao Xi; Lufeng Zheng
Journal:  J Hematol Oncol       Date:  2020-05-26       Impact factor: 17.388

5.  High content screening identifies monensin as an EMT-selective cytotoxic compound.

Authors:  Marion Vanneste; Qin Huang; Mengshi Li; Devon Moose; Lei Zhao; Mark A Stamnes; Michael Schultz; Meng Wu; Michael D Henry
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

Review 6.  Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand.

Authors:  Karim Farmanpour-Kalalagh; Arman Beyraghdar Kashkooli; Alireza Babaei; Ali Rezaei; Alexander R van der Krol
Journal:  Front Plant Sci       Date:  2022-02-07       Impact factor: 5.753

Review 7.  Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.

Authors:  Ernestina M De Francesco; Federica Sotgia; Michael P Lisanti
Journal:  Biochem J       Date:  2018-05-09       Impact factor: 3.857

8.  New Drug Discovery Paradigms for Retinal Diseases: A Focus on Retinal Organoids.

Authors:  Davis M Aasen; M Natalia Vergara
Journal:  J Ocul Pharmacol Ther       Date:  2019-05-06       Impact factor: 2.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.